JP2019507130A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507130A5
JP2019507130A5 JP2018539873A JP2018539873A JP2019507130A5 JP 2019507130 A5 JP2019507130 A5 JP 2019507130A5 JP 2018539873 A JP2018539873 A JP 2018539873A JP 2018539873 A JP2018539873 A JP 2018539873A JP 2019507130 A5 JP2019507130 A5 JP 2019507130A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
heterocycloalkyl
compound according
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018539873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507130A (ja
JP6924766B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015953 external-priority patent/WO2017136395A1/en
Publication of JP2019507130A publication Critical patent/JP2019507130A/ja
Publication of JP2019507130A5 publication Critical patent/JP2019507130A5/ja
Priority to JP2021126415A priority Critical patent/JP7257462B2/ja
Application granted granted Critical
Publication of JP6924766B2 publication Critical patent/JP6924766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018539873A 2016-02-01 2017-02-01 ベンゾピラゾール化合物及びその類似体 Active JP6924766B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021126415A JP7257462B2 (ja) 2016-02-01 2021-08-02 ベンゾピラゾール化合物及びその類似体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662289653P 2016-02-01 2016-02-01
US62/289,653 2016-02-01
PCT/US2017/015953 WO2017136395A1 (en) 2016-02-01 2017-02-01 Benzopyrazole compounds and analogues thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021126415A Division JP7257462B2 (ja) 2016-02-01 2021-08-02 ベンゾピラゾール化合物及びその類似体

Publications (3)

Publication Number Publication Date
JP2019507130A JP2019507130A (ja) 2019-03-14
JP2019507130A5 true JP2019507130A5 (enExample) 2020-02-27
JP6924766B2 JP6924766B2 (ja) 2021-08-25

Family

ID=59500923

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018539873A Active JP6924766B2 (ja) 2016-02-01 2017-02-01 ベンゾピラゾール化合物及びその類似体
JP2021126415A Active JP7257462B2 (ja) 2016-02-01 2021-08-02 ベンゾピラゾール化合物及びその類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021126415A Active JP7257462B2 (ja) 2016-02-01 2021-08-02 ベンゾピラゾール化合物及びその類似体

Country Status (30)

Country Link
US (3) US10849883B2 (enExample)
EP (2) EP3925956B1 (enExample)
JP (2) JP6924766B2 (enExample)
KR (1) KR102828456B1 (enExample)
CN (2) CN115490751B (enExample)
AR (1) AR107488A1 (enExample)
AU (1) AU2017213768B2 (enExample)
CA (1) CA3011549A1 (enExample)
CO (1) CO2018008916A2 (enExample)
CY (1) CY1124652T1 (enExample)
DK (1) DK3411411T6 (enExample)
EA (1) EA039719B1 (enExample)
ES (2) ES2982426T3 (enExample)
HR (1) HRP20210926T4 (enExample)
HU (1) HUE055258T2 (enExample)
IL (2) IL290154B2 (enExample)
LT (1) LT3411411T (enExample)
MA (1) MA43979B1 (enExample)
MD (1) MD3411411T2 (enExample)
MX (2) MX2018008869A (enExample)
MY (1) MY201629A (enExample)
PH (1) PH12018501537B1 (enExample)
PL (1) PL3411411T6 (enExample)
PT (1) PT3411411T (enExample)
RS (1) RS62187B2 (enExample)
SG (2) SG11201805940QA (enExample)
SI (1) SI3411411T1 (enExample)
SM (1) SMT202100494T1 (enExample)
TW (2) TWI747873B (enExample)
WO (1) WO2017136395A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
TWI873092B (zh) 2018-04-06 2025-02-21 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3856164B1 (en) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
BR112021011727A2 (pt) 2018-12-17 2021-08-31 Achillion Pharmaceuticals, Inc Dosagem direcionada para o tratamento de distúrbios mediados do complemento
CN113164508B (zh) 2018-12-19 2025-07-08 达萨玛治疗公司 与神经保护剂组合的sarm1抑制剂
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
UY38912A (es) 2019-10-09 2021-05-31 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
TWI890699B (zh) * 2019-10-09 2025-07-21 美商百歐克斯製藥公司 口服補體因子d抑制劑
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
AR121715A1 (es) 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
CN113512025B (zh) * 2020-07-31 2023-01-06 四川大学 一种吲唑酯类化合物及其制药用途
WO2025080823A1 (en) 2023-10-11 2025-04-17 Regeneron Pharmaceuticals, Inc. Treatment of macular degeneration with complement factor d (cfd) inhibitors
CN119638611B (zh) * 2024-12-08 2025-10-31 胥江生物科技(苏州)有限公司 N-乙酰-5-羟色胺衍生物、免疫原、抗体及检测试剂制备与应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
WO1991012779A1 (en) 1990-02-28 1991-09-05 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
EP0746544B1 (en) 1994-02-22 1998-09-09 Merrell Pharmaceuticals Inc. Novel indole derivatives useful to treat estrogen-related neoplasms and disorders
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
CA2256631A1 (en) 1996-09-04 1998-03-12 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
CN1230178A (zh) 1996-09-10 1999-09-29 麦地诺克斯公司 含聚二硫代氨基甲酸酯的大分子和其用于治疗和诊断应用的用途
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
WO2003065789A2 (en) * 2002-02-08 2003-08-14 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
EP1433778A1 (en) * 2002-12-23 2004-06-30 Jerini AG Use of nitriles as rotamase inhibitors
US7335644B2 (en) * 2003-03-31 2008-02-26 Council Of Scientific And Industrial Research Anti-hypertensive molecules and process for preparation thereof
JP2007008914A (ja) * 2004-10-27 2007-01-18 Nissan Chem Ind Ltd 置換ジアミン化合物および農園芸用殺菌剤
US7807704B2 (en) * 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
WO2009106980A2 (en) * 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
US8791102B2 (en) * 2008-10-17 2014-07-29 Exelixis, Inc. Acetanilide sphingosine-1-phosphate receptor antagonists
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
CN102464654B (zh) * 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
KR20140027090A (ko) * 2011-01-04 2014-03-06 노파르티스 아게 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
US10093674B2 (en) 2011-05-31 2018-10-09 Brandeis University Supramolecular nanofibers and hydrogels based on nucleic acids functionalized with nucleobases
WO2012166706A2 (en) 2011-05-31 2012-12-06 Brandeis University Supramolecular nanofibers and hydrogels based on oligopeptides functionalized with nucleobases
EP2548864B1 (en) 2011-07-22 2014-02-19 Université Joseph Fourier Novel bis-indolic derivatives, a process for preparing the same and their uses as a drug
AU2012308570B2 (en) 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
US9187474B2 (en) * 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
JP6180514B2 (ja) 2012-05-04 2017-08-16 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
EP3210627B1 (en) 2012-07-12 2022-12-21 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
EP2872503B1 (en) 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
AR092684A1 (es) 2012-09-27 2015-04-29 Hoffmann La Roche Compuestos de sulfonamida sustituidos
CN110563700A (zh) * 2013-03-15 2019-12-13 德西费拉制药有限责任公司 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
KR20160118368A (ko) * 2014-02-25 2016-10-11 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개된 장애의 치료를 위한 에터 화합물
WO2016205010A1 (en) * 2015-06-19 2016-12-22 The Regents Of The University Of California Treating vasculature related diseases or disorders using nanoparticles
WO2017035411A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035415A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035413A2 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物

Similar Documents

Publication Publication Date Title
JP2019518766A5 (enExample)
JP2018515581A5 (enExample)
JP2013532652A5 (enExample)
JP2019529490A5 (enExample)
JP2009505988A5 (enExample)
JP2018526399A5 (enExample)
JP2009504669A5 (enExample)
JP2009504772A5 (enExample)
JP2020517616A5 (enExample)
JP2018535967A5 (enExample)
RU2013158933A (ru) Новые модуляторы иммунной системы родственные заявки
RU2012149448A (ru) Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры
JP2012505235A5 (enExample)
JP2013508378A5 (enExample)
JP2016522266A5 (enExample)
RU2012110007A (ru) Имидазохинолины в качестве двойных ингибиторов липидкиназы и mtor
JP2009515988A5 (enExample)
IL274504B1 (en) 2ACSS inhibitors and methods of their use
HRP20210926T4 (hr) Derivati 1h-indazol-3-karboksamida i povezani spojevi kao inhibitori faktora d za liječenje bolesti karakteriziranih pojačanom djelatnošću sustava komplemenata, kao npr. imunološki poremećaji
JP2009524691A5 (enExample)
JP2020535124A5 (enExample)
JP2016537382A5 (enExample)
JP2013536188A5 (enExample)
JP2023164918A5 (enExample)
JP2014500265A5 (enExample)